<DOC>
	<DOCNO>NCT02792088</DOCNO>
	<brief_summary>To prove study drug noninferior control drug proportion subject show HBV DNA undetected ( less 400 copies/mL ( 69 IU/mL ) ) 48th week 48-week administration Besifovir 150 mg , Tenofovir 300 mg control drug chronic hepatitis B patient</brief_summary>
	<brief_title>Study Assess Antiviral Activity Safety Endpoints Treatment Besifovir 150mg Compared Tenofovir 300mg Chronic Hepatitis B Patients Who Have Resistance Nucleoside Analogues</brief_title>
	<detailed_description>- Screening Period Subject registration conduct confirm selection exclusion criterion write consent form obtain within 42 day clinical trial drug administration . - Baseline Subjects visit date start clinical trial drug administration randomize test group control group ratio 1:1 . Double blindness apply group . - Treatment period Subjects orally administer clinical trial drug q.ds.i.d . 48 week visit 0 , 4th , 12th , 24th , 36th , 48th week HBV DNA test , laboratory test , physical test , vital sign , adverse event . - Follow-up period Subjects provide appropriate treatment complete 48-week trial drop . Subjects visit 60th week follow-up adverse event , acute deterioration hepatitis B , HBV DNA test result . If treatment conduct 48-week administration , subject visit interval four week follow-up visit ( 60th week ) test 24th week visit ( Visit 5 ) conduct . However , subject participate 48-week separate extend trial conduct 48-week administration clinical trial follow-up period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Patients show positive HBsAg history chronic hepatitis B last six month screen Patients show positive HBsAg screening Have develop nucleoside analogue resistant HB Had receive nucleotide analogue Was coinfected hepatitis C hepatitis D virus Human Immunodeficiency Virus Had confirmation adefovir drug resistant mutation At screening , alphafetoprotein ( AFP ) value &gt; 20 ng/mL followup ultrasonography perform prior baseline show finding indicative HCC</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HBV</keyword>
</DOC>